Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

BACKGROUND: Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immunomodulatory mechanisms of action, demonstrated clinical benefit as monotherapy or in combination with established regimens in patients with multiple myeloma with one or more prior lines of therapy. CASE PRESE...

Descripción completa

Detalles Bibliográficos
Autores principales: Usmani, Saad Z., Khan, Imran, Chiu, Christopher, Foureau, David, Druhan, Lawrence J., Rigby, Katherine, Casneuf, Tineke, Sasser, A. Kate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5804097/
https://www.ncbi.nlm.nih.gov/pubmed/29445583
http://dx.doi.org/10.1186/s40164-018-0096-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5804097/
https://www.ncbi.nlm.nih.gov/pubmed/29445583
http://dx.doi.org/10.1186/s40164-018-0096-7

Ejemplares similares